Skip to main content
Erschienen in:

10.08.2020 | Original Article

Clinicopathologic and survival analysis of patients with adenoid cystic carcinoma of vulva: single-institution experience

verfasst von: Jun Zhu, Lina Yin, Qifeng Wang, Xiaohua Wu, Guihao Ke

Erschienen in: International Journal of Clinical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to elucidate our experience in the diagnosis and treatment of adenoid cystic carcinoma of the vulva (ACC-vulva) and to assess the clinicopathological characteristics and prognosis among ACC-vulva patients.

Methods

A retrospective study of seventeen patients was performed to illustrate the demographic information, clinical performance, pathological characteristics, treatment modality, and development of local recurrence or distant metastasis, as well as the survival outcome.

Results

The median age at diagnosis was 56 years (range, 26–71 years). Radical local excision was performed on fifteen patients, and two patient received radical hemi-vulvectomy. Six patients received ipsilateral inguinal lymphadenectomy. Involvement of the resection margin was observed in six patients. The postoperative pathologic diagnosis showed no proof of inguinal lymph node metastasis in all the six patients receiving lymphadenectomy. However, the perineural invasion was observed in all patients. Postoperative adjuvant radiotherapy was applied to five patients who had positive resection margin. The mean survival time except for that in four patients (recent case) was 47.8 months (range, 23–78 months).

Conclusion

Radical resection towards negative margins seems to be acceptable as initial treatment. Adjuvant radiotherapy is a preferable treatment modality for patients with high-risk factors pathologically or patients with local recurrence.
Literatur
1.
Zurück zum Zitat Yang SY, Lee JW, Kim WS et al (2006) Adenoid cystic carcinoma of the Bartholin’s gland: report of two cases and review of the literature. Gynecol Oncol 100(2):422–425CrossRef Yang SY, Lee JW, Kim WS et al (2006) Adenoid cystic carcinoma of the Bartholin’s gland: report of two cases and review of the literature. Gynecol Oncol 100(2):422–425CrossRef
2.
Zurück zum Zitat Alsan CI, Vinh-Hung V, Eren F et al (2011) Adenoid cystic carcinoma of the Bartholin’s gland: case report and systematic review of the literature. Eur J Gynaecol Oncol 32(5):567–572PubMed Alsan CI, Vinh-Hung V, Eren F et al (2011) Adenoid cystic carcinoma of the Bartholin’s gland: case report and systematic review of the literature. Eur J Gynaecol Oncol 32(5):567–572PubMed
3.
Zurück zum Zitat Sisodia SM, Khan WA, Ansari SA et al (2013) Adenoid cystic carcinoma of Bartholin’s gland: Report of a case and review of literature. South Asian J Cancer 2(1):18PubMedPubMedCentral Sisodia SM, Khan WA, Ansari SA et al (2013) Adenoid cystic carcinoma of Bartholin’s gland: Report of a case and review of literature. South Asian J Cancer 2(1):18PubMedPubMedCentral
4.
Zurück zum Zitat Hou JL, Wu LY, Zhang HT et al (2010) Clinicopathological characteristics of six patients with adenoid cystic carcinoma of the Bartholin gland. Zhonghua Zhong Liu Za Zhi 32(4):290–293PubMed Hou JL, Wu LY, Zhang HT et al (2010) Clinicopathological characteristics of six patients with adenoid cystic carcinoma of the Bartholin gland. Zhonghua Zhong Liu Za Zhi 32(4):290–293PubMed
5.
Zurück zum Zitat Li J, Cai Y, Ke G et al (2015) Validation of the new FIGO staging system (2009) for vulvar cancer in the Chinese population. Gynecol Oncol 137(2):274–279CrossRef Li J, Cai Y, Ke G et al (2015) Validation of the new FIGO staging system (2009) for vulvar cancer in the Chinese population. Gynecol Oncol 137(2):274–279CrossRef
6.
Zurück zum Zitat Xing D, Schoolmeester JK, Ren Z et al (2016) Lower female genital tract tumors with adenoid cystic differentiation: p16 expression and high-risk HPV detection. Am J Surg Pathol 40(4):529–536CrossRef Xing D, Schoolmeester JK, Ren Z et al (2016) Lower female genital tract tumors with adenoid cystic differentiation: p16 expression and high-risk HPV detection. Am J Surg Pathol 40(4):529–536CrossRef
7.
Zurück zum Zitat Brill LB 2nd, Kanner WA, Fehr A et al (2011) Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 24(9):1169–1176CrossRef Brill LB 2nd, Kanner WA, Fehr A et al (2011) Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 24(9):1169–1176CrossRef
8.
Zurück zum Zitat Persson M, Andren Y, Mark J et al (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106(44):18740–18744CrossRef Persson M, Andren Y, Mark J et al (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106(44):18740–18744CrossRef
9.
Zurück zum Zitat Xing D, Bakhsh S, Melnyk N et al (2017) Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. Int J Gynecol Pathol 36(3):289–293CrossRef Xing D, Bakhsh S, Melnyk N et al (2017) Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. Int J Gynecol Pathol 36(3):289–293CrossRef
10.
Zurück zum Zitat Mitani Y, Li J, Rao PH et al (2010) Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 16(19):4722–4731CrossRef Mitani Y, Li J, Rao PH et al (2010) Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 16(19):4722–4731CrossRef
11.
Zurück zum Zitat Andersson MK, Mangiapane G, Nevado PT et al (2020) ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. Oncogenesis 9(1):5CrossRef Andersson MK, Mangiapane G, Nevado PT et al (2020) ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. Oncogenesis 9(1):5CrossRef
12.
Zurück zum Zitat Lelle RJ, Davis KP, Roberts JA (1994) Adenoid cystic carcinoma of the Bartholin’s gland: the University of Michigan experience. Int J Gynecol Cancer 4(3):145–149CrossRef Lelle RJ, Davis KP, Roberts JA (1994) Adenoid cystic carcinoma of the Bartholin’s gland: the University of Michigan experience. Int J Gynecol Cancer 4(3):145–149CrossRef
13.
Zurück zum Zitat Nasu K, Kawano Y, Takai N et al (2005) Adenoid cystic carcinoma of Bartholin’s Gland. Case report with review of the literature. Gynecol Obstet Invest 59(1):54–58CrossRef Nasu K, Kawano Y, Takai N et al (2005) Adenoid cystic carcinoma of Bartholin’s Gland. Case report with review of the literature. Gynecol Obstet Invest 59(1):54–58CrossRef
14.
Zurück zum Zitat Copeland LJ, Sneige N, Gershenson DM et al (1986) Adenoid cystic carcinoma of Bartholin gland. Obstet Gynecol 67(1):115–120PubMed Copeland LJ, Sneige N, Gershenson DM et al (1986) Adenoid cystic carcinoma of Bartholin gland. Obstet Gynecol 67(1):115–120PubMed
15.
Zurück zum Zitat Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 33(6):905–911CrossRef Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 33(6):905–911CrossRef
16.
Zurück zum Zitat Coca-Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of the head and neck–An update. Oral Oncol 51(7):652–661CrossRef Coca-Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of the head and neck–An update. Oral Oncol 51(7):652–661CrossRef
17.
Zurück zum Zitat Hitre E, Budai B, Takacsi-Nagy Z et al (2013) Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 109(5):1117–1122CrossRef Hitre E, Budai B, Takacsi-Nagy Z et al (2013) Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 109(5):1117–1122CrossRef
18.
Zurück zum Zitat Chang Y, Wu W, Chen H: Adenoid cystic carcinoma of the Bartholin’s gland: a case report and literature review. J Int Med Res 2019:300060519863540 Chang Y, Wu W, Chen H: Adenoid cystic carcinoma of the Bartholin’s gland: a case report and literature review. J Int Med Res 2019:300060519863540
19.
Zurück zum Zitat Yoon G, Kim HS, Lee YY et al (2015) Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. Int J Clin Exp Pathol 8(5):5688–5694PubMedPubMedCentral Yoon G, Kim HS, Lee YY et al (2015) Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. Int J Clin Exp Pathol 8(5):5688–5694PubMedPubMedCentral
20.
Zurück zum Zitat Rosenberg P, Simonsen E, Risberg B (1989) Adenoid cystic carcinoma of Bartholin’s gland: a report of five new cases treated with surgery and radiotherapy. Gynecol Oncol 34(2):145–147CrossRef Rosenberg P, Simonsen E, Risberg B (1989) Adenoid cystic carcinoma of Bartholin’s gland: a report of five new cases treated with surgery and radiotherapy. Gynecol Oncol 34(2):145–147CrossRef
21.
Zurück zum Zitat Lopez-Varela E, Oliva E, McIntyre JF et al (2007) Primary treatment of Bartholin’s gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases. Int J Gynecol Cancer 17(3):661–667CrossRef Lopez-Varela E, Oliva E, McIntyre JF et al (2007) Primary treatment of Bartholin’s gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases. Int J Gynecol Cancer 17(3):661–667CrossRef
22.
Zurück zum Zitat Wheelock JB, Goplerud DR, Dunn LJ et al (1984) Primary carcinoma of the Bartholin gland: a report of ten cases. Obstet Gynecol 63(6):820–824PubMed Wheelock JB, Goplerud DR, Dunn LJ et al (1984) Primary carcinoma of the Bartholin gland: a report of ten cases. Obstet Gynecol 63(6):820–824PubMed
23.
Zurück zum Zitat Min R, Siyi L, Wenjun Y et al (2012) Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. Int J Oral Maxillofac Surg 41(8):952–957CrossRef Min R, Siyi L, Wenjun Y et al (2012) Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. Int J Oral Maxillofac Surg 41(8):952–957CrossRef
24.
Zurück zum Zitat Woida FM, Ribeiro-Silva A (2007) Adenoid cystic carcinoma of the Bartholin gland: an overview. Arch Pathol Lab Med 131(5):796–798PubMed Woida FM, Ribeiro-Silva A (2007) Adenoid cystic carcinoma of the Bartholin gland: an overview. Arch Pathol Lab Med 131(5):796–798PubMed
25.
Zurück zum Zitat Milchgrub S, Wiley EL, Vuitch F et al (1994) The tubular variant of adenoid cystic carcinoma of the Bartholin’s gland. Am J Clin Pathol 101(2):204–208CrossRef Milchgrub S, Wiley EL, Vuitch F et al (1994) The tubular variant of adenoid cystic carcinoma of the Bartholin’s gland. Am J Clin Pathol 101(2):204–208CrossRef
26.
Zurück zum Zitat Ramanah R, Allam-Ndoul E, Baeza C et al (2013) Brain and lung metastasis of Bartholin’s gland adenoid cystic carcinoma: a case report. J Med Case Rep 7:208CrossRef Ramanah R, Allam-Ndoul E, Baeza C et al (2013) Brain and lung metastasis of Bartholin’s gland adenoid cystic carcinoma: a case report. J Med Case Rep 7:208CrossRef
Metadaten
Titel
Clinicopathologic and survival analysis of patients with adenoid cystic carcinoma of vulva: single-institution experience
verfasst von
Jun Zhu
Lina Yin
Qifeng Wang
Xiaohua Wu
Guihao Ke
Publikationsdatum
10.08.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 12/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01764-0

Neu im Fachgebiet Onkologie

Junge Brustkrebspatientinnen zum Durchhalten motivieren

Patientinnen, die in jungen Jahren an Hormonrezeptor-positivem Brustkrebs erkranken, neigen dazu, die adjuvante endokrine Therapie auszusetzen oder abzubrechen. Die schlechte Therapiepersistenz scheint die Rückkehr des Tumors zu begünstigen.

Mehr Nierenkrebs bei regelmäßiger Einnahme von NSAR?

In der Allgemeinbevölkerung ist die wiederholte Verordnung von nichtsteroidalen Antirheumatika (NSAR) mit einem leicht erhöhten Nierenkrebsrisiko assoziiert. Dieses Ergebnis einer schwedischen Registerstudie ist allerdings mit einigen Fragezeichen zu versehen. 

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.